Phase 4 N=30 Spironolactone After Liver Transplant
Transplant, Liver
Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Comparison of 1,550 and 755 Laser in a Split-face Trial
Acne Scars - Mixed Atrophic and Hypertrophic
Primary: Number of Half Faces to Achieve at Least 25% Improvement in Acne Scarring at Week 24 by Blinded Photo Reviewer — 18; 17 half faces
Phase 4 N=59 Synthetic vs Natural Estrogen in Combined Oral Contraception
Contraception
Primary: Matsuda Index- Whole Body Insulin Sensitivity Index — -1.02; -0.10; -1.45 units on a scale — p=0.27
Phase 2 N=52 Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 8 percentage of participants
N/A N=37 PREVAIL VII: Cataract Surgery in Ebola Survivors
Cataract
Primary: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue — 0 Participants
N/A N=66 Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery
Obstetric Anal Sphincter Injury · Vaginal Electrical Stimulation
Primary: Anal Incontinence — 12; 4 Scores on a scale — p=0.04
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=140 Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence
Venous Hypertension Ulcers · Venous Stasis Ulcer · Venous Ulcer
Primary: Number of Participants With Ulcer Recurrence — 6; 3; 11; 5 participants — p=0.091
N/A N=3,245 Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
Flu, Human · Influenza, Human · Covid19
Primary: Rating of Sender — .1828917; -.0750636; .0997998; -.5397662 index
N/A N=344 Non-Interventional Study on the Tolerability and Efficacy of IVIG
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
Primary: Adverse Drug Reactions — 17; 37; 0; 1 Participants
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
Phase 3 N=69 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) — 8.6; -26.9 Percentage of change — p=<0.0001
Phase 2 N=102 Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
N/A N=80 CPI Training for Parents of Children With ASD
Autism Spectrum Disorder
Primary: Change in the Child Adjustment and Parent Efficacy Scale-Developmental Disability Self-Efficacy Scale Total Score — 8.3; 2.5 units on a scale — p=0.11
N/A N=6 Initial Chronic Human Validation Study: Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System
Ventricular Tachyarrhythmias
Primary: Number of Participants With a Successful Induced Ventricular Fibrillation Conversion — 6 Participants